Patents Assigned to Astellas Pharma Inc.
  • Patent number: 11180554
    Abstract: [Problem] Provided is an anti-human CD73 antibody which is enhanced as compared to the antibody in the prior art and has an ability of recovering AMP-dependently suppressed T cell functions. [Means for Solution] Provided is an anti-human CD73 antibody comprising a heavy chain variable region comprising CDR1 consisting of the amino acid sequence of amino acid numbers 31 to 35 of SEQ ID NO: 2, CDR2 consisting of the amino acid sequence of amino acid numbers 50 to 66 of SEQ ID NO: 2, and CDR3 consisting of the amino acid sequence of amino acid numbers 99 to 112 of SEQ ID NO: 2, and a light chain variable region comprising CDR1 consisting of the amino acid sequence of amino acid numbers 24 to 34 of SEQ ID NO: 4, CDR2 consisting of the amino acid sequence of amino acid numbers 50 to 56 of SEQ ID NO: 4, and CDR3 consisting of the amino acid sequence of amino acid numbers 89 to 98 of SEQ ID NO: 4.
    Type: Grant
    Filed: December 12, 2017
    Date of Patent: November 23, 2021
    Assignee: Astellas Pharma Inc.
    Inventors: Masahito Sato, Hanae Toyonaga, Fumio Osaki, Tomohiro Eguchi
  • Publication number: 20210355464
    Abstract: Polynucleotides comprising the following base sequences: (a) a base sequence encoding a fusion protein of a nuclease-deficient CRISPR effector protein and a transcription activator, and (b) a base sequence encoding a guide RNA targeting a continuous region of 18 to 24 nucleotides in length in a region set forth in SEQ ID NO: 104, 105, 135, 141, 153, 167, or 172 in the expression regulatory region of human Utrophin gene are expected to be useful for treating or preventing DUCHENNE muscular dystrophy or BECKER muscular dystrophy.
    Type: Application
    Filed: May 14, 2021
    Publication date: November 18, 2021
    Applicants: ASTELLAS PHARMA INC., MODALIS THERAPEUTICS CORPORATION
    Inventors: Eiji YOSHIMI, Katsuro YOSHIOKA, Tetsuya YAMAGATA, Yuanbo QIN, Iain Robert THOMPSON, Nidhi KHANNA
  • Publication number: 20210346392
    Abstract: In a pharmaceutical composition for oral administration comprising 6-(4,4-dimethylcyclohexyl)-4-[(1,1-dioxo-1?6-thiomorpholin-4-yl)methyl]-2-methylthieno[2,3-d]pyrimidine or a pharmaceutically acceptable salt thereof, a stable pharmaceutical composition for oral administration with rapid drug dissolution properties is provided. The pharmaceutical composition for oral administration contains a water-swellable substance, which is a polymer compound obtained by condensation polymerization of ?-glucose, a polymer compound obtained by condensation polymerization of ?-glucose, or a polymer compound having a pyrrolidone functional group.
    Type: Application
    Filed: August 30, 2019
    Publication date: November 11, 2021
    Applicant: ASTELLAS PHARMA INC.
    Inventors: Ryo KOJIMA, Toshiro SAKAI, Ryota AZUMA, Marina TANAKA
  • Publication number: 20210340276
    Abstract: Provided are a conjugate comprising an anti-human MUC1 antibody Fab fragment and a peptide linker and/or a ligand, a composition for diagnosis and/or a pharmaceutical composition comprising the conjugate, a method for diagnosing and/or treating a cancer using the conjugate, and the like. In the conjugate used, the anti-human MUC1 antibody Fab fragment is bound to the ligand via the peptide linker or the like.
    Type: Application
    Filed: May 17, 2019
    Publication date: November 4, 2021
    Applicant: Astellas Pharma Inc.
    Inventors: Toru ASANO, Yorikata SANO, Akifumi MORINAKA, Hiroki SHIRAI, Kazunori HIRAYAMA, Michinori AKAIWA, Hiroyoshi YAMADA, Nobuyuki SHIRAISHI
  • Publication number: 20210340549
    Abstract: [Problem] To provide a nucleic acid expected to be useful for treating mite allergy. [Means to be solved] Provided is a nucleic acid comprising a nucleotide sequence encoding a chimeric protein, wherein the nucleic acid comprises a nucleotide sequence encoding a signal peptide, a nucleotide sequence encoding an intra-organelle stabilizing domain of LAMP, a nucleotide sequence encoding an allergen domain comprising Der p 1, Der p 2, Der p 23, and Der p 7, a nucleotide sequence encoding a transmembrane domain and a nucleotide sequence encoding an endosomal/lysosomal targeting domain of LAMP in this order.
    Type: Application
    Filed: July 15, 2021
    Publication date: November 4, 2021
    Applicant: Astellas Pharma Inc.
    Inventors: Takanori MARUI, Masao UCHIDA
  • Publication number: 20210315951
    Abstract: The present invention provides a combination therapy of genetically modified vaccinia virus (particularly oncolytic vaccinia virus) and another cancer therapy for use in treating cancer, and a pharmaceutical composition and a combination kit for use in the therapy. More specifically, the invention provides a therapy with vaccinia virus containing a polynucleotide encoding interleukin-7 (IL-7) and a polynucleotide encoding interleukin-12 (IL-12) in combination with an immune checkpoint inhibitor, and a pharmaceutical composition and a combination kit for use in the therapy.
    Type: Application
    Filed: September 25, 2019
    Publication date: October 14, 2021
    Applicant: ASTELLAS PHARMA INC.
    Inventors: Shinsuke NAKAO, Tatsuya KAWASE
  • Publication number: 20210290618
    Abstract: A pharmaceutical composition is suitable for treating AXL-related cancer. The cancer can be cancer with high expression of AXL. The cancer can also be cancer which has acquired resistance by the activation of AXL against therapy with an anticancer agent. Specific diamino heterocyclic carboxamide compounds have an AXL inhibitory action, and pharmaceutical compositions comprising these compounds as an active ingredient have a therapeutic effect on AXL-related cancer. This AXL-related cancer can be cancer with high expression of AXL and/or cancer which has acquired resistance by the activation of AXL against therapy with an anticancer agent.
    Type: Application
    Filed: May 21, 2021
    Publication date: September 23, 2021
    Applicant: ASTELLAS PHARMA INC.
    Inventors: Tomohiro EGUCHI, Masamichi MORI, Yoko YAMAKI
  • Publication number: 20210292853
    Abstract: The purpose is to reveal a polynucleotide that is a novel causal gene of pancreatic cancer and thereby provide a method for detecting the polynucleotide or a polypeptide encoded thereby to select a subject positive for the polynucleotide or polypeptide and a method expected to be useful for to identify patients suitable for therapies and a primer set therefor and a kit for detection. In the method, a polynucleotide comprising a fusion point of a part of a CLDN18 gene and an ARHGAP6 gene or a polynucleotide comprising a fusion point of a part of a CLDN18 gene and an ARHGAP26 gene, or a fusion protein encoded thereby is detected. The primer set comprises a sense primer designed for a part encoding CLDN18 and an antisense primer designed for a part encoding ARHGAP6 or a part encoding ARHGAP26.
    Type: Application
    Filed: June 2, 2021
    Publication date: September 23, 2021
    Applicants: Astellas Pharma Inc., National Cancer Center
    Inventor: Hiroki SASAKI
  • Patent number: 11059889
    Abstract: Described herein are novel anti-human Ig? antibodies, as well as methods for making the antibodies and using the antibodies to treat or prevent autoimmune disease.
    Type: Grant
    Filed: April 23, 2019
    Date of Patent: July 13, 2021
    Assignee: Astellas Pharma Inc.
    Inventors: Daisuke Yamajuku, Mutsumi Seki, Takashi Honda, Satoshi Kubo, Shinji Soga, Akifumi Morinaka
  • Patent number: 11053553
    Abstract: The purpose is to reveal a polynucleotide that is a novel causal gene of pancreatic cancer and thereby provide a method for detecting the polynucleotide or a polypeptide encoded thereby to select a subject positive for the polynucleotide or polypeptide and a method expected to be useful for to identify patients suitable for therapies and a primer set therefor and a kit for detection. In the method, a polynucleotide comprising a fusion point of a part of a CLDN18 gene and an ARHGAP6 gene or a polynucleotide comprising a fusion point of a part of a CLDN18 gene and an ARHGAP26 gene, or a fusion protein encoded thereby is detected. The primer set comprises a sense primer designed for a part encoding CLDN18 and an antisense primer designed for a part encoding ARHGAP6 or a part encoding ARHGAP26.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: July 6, 2021
    Assignees: Astellas Pharma Inc., National Cancer Center
    Inventor: Hiroki Sasaki
  • Patent number: 11045468
    Abstract: A pharmaceutical composition is suitable for treating AXL-related cancer. The cancer can be cancer with high expression of AXL. The cancer can also be cancer which has acquired resistance by the activation of AXL against therapy with an anticancer agent. Specific diamino heterocyclic carboxamide compounds have an AXL inhibitory action, and pharmaceutical compositions comprising these compounds as an active ingredient have a therapeutic effect on AXL-related cancer. This AXL-related cancer can be cancer with high expression of AXL and/or cancer which has acquired resistance by the activation of AXL against therapy with an anticancer agent.
    Type: Grant
    Filed: February 3, 2015
    Date of Patent: June 29, 2021
    Assignee: ASTELLAS PHARMA INC.
    Inventors: Tomohiro Eguchi, Masamichi Mori, Yoko Yamaki
  • Patent number: 11046770
    Abstract: [Problem] Provided is an anti-human BDCA-2 antibody for preventing or treating an autoimmune disease by binding to a human BDCA-2 to control the function of a plasmacytoid dendritic cell through human BDCA-2.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: June 29, 2021
    Assignee: Astellas Pharma Inc.
    Inventors: Shinsuke Nakao, Masayuki Ito, Yoshiyuki Tenda
  • Publication number: 20210163549
    Abstract: [Problem] To provide a nucleic acid expected to be useful for treating crustacean allergy. [Means to be solved] Provided is a nucleic acid comprising a nucleotide sequence encoding a chimeric protein, wherein the nucleic acid comprises a nucleotide sequence encoding a signal peptide, a nucleotide sequence encoding an intra-organelle stabilizing domain of LAMP, a nucleotide sequence encoding an allergen domain comprising Lit v 1, Lit v 4, and Lit v 3, a nucleotide sequence encoding a transmembrane domain and a nucleotide sequence encoding an endosomal/lysosomal targeting domain of LAMP in this order.
    Type: Application
    Filed: May 10, 2019
    Publication date: June 3, 2021
    Applicant: Astellas Pharma Inc.
    Inventor: Takanori MARUI
  • Publication number: 20210163533
    Abstract: An object of the present invention is to provide a cell penetrating peptide having a penetrating ability into cells. The present inventors provided a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 1, a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 2 and a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 3; and a complex comprising any one of the cell penetrating peptide and a functional molecule.
    Type: Application
    Filed: December 10, 2018
    Publication date: June 3, 2021
    Applicants: Astellas Pharma Inc., National Center for Global Health and Medicine, Hiroshima University
    Inventors: Hideki Endo, Yukihito ISHIZAKA, Akira ISHIGURO, Tomoki TAKASHINA, Takashi YAMAMOTO, Tetsushi SAKUMA
  • Publication number: 20210163957
    Abstract: [Problem] To provide a nucleic acid expected to be useful for treating mite allergy. [Means to be solved] Provided is a nucleic acid comprising a nucleotide sequence encoding a chimeric protein, wherein the nucleic acid comprises a nucleotide sequence encoding a signal peptide, a nucleotide sequence encoding an intra-organelle stabilizing domain of LAMP, a nucleotide sequence encoding an allergen domain comprising Der p 1, Der p 2, Der p 23, and Der p 7, a nucleotide sequence encoding a transmembrane domain and a nucleotide sequence encoding an endosomal/lysosomal targeting domain of LAMP in this order.
    Type: Application
    Filed: May 10, 2019
    Publication date: June 3, 2021
    Applicant: Astellas Pharma Inc.
    Inventors: Takanori MARUI, Masao UCHIDA
  • Publication number: 20210147529
    Abstract: A novel pharmaceutical composition for suppressing atrial fibrillation that has an action mechanism that does not affect the normal heart function is provided. A pharmaceutical composition including an anti-human NGF antibody or antigen binding fragment thereof as an active ingredient is provided.
    Type: Application
    Filed: May 14, 2019
    Publication date: May 20, 2021
    Applicant: Astellas Pharma Inc.
    Inventors: Kohsuke SHAKUSHIRO, Toshiaki AOKI
  • Patent number: 10994011
    Abstract: Provided is a stable pharmaceutical composition comprising an anti-human TSLP receptor antibody, capable of inhibiting the generation of chemically modified substances, such as deamidated forms and oxidized forms, or degradants, or multimers. The pharmaceutical composition comprises an anti-human TSLP receptor antibody, a pharmaceutically acceptable buffer, arginine or a pharmaceutically acceptable salt thereof, and a surfactant.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: May 4, 2021
    Assignee: ASTELLAS PHARMA INC.
    Inventors: Megumi Ikeda, Akinori Chikushi
  • Publication number: 20210113529
    Abstract: Provided is a pharmaceutical for preventing or treating an ophthalmic disease associated with intraocular neovascularization and/or increased intraocular vascular permeability. The inventors of the present invention have made investigations on a pharmaceutical for preventing or treating an ophthalmic disease associated with intraocular neovascularization and/or increased intraocular vascular permeability, and have confirmed that a selective S1P receptor agonist having agonist activity at an S1P1 receptor has an intraocular neovascularization-reducing action and an intraocular vascular permeability-reducing action, thus completing the present invention.
    Type: Application
    Filed: February 1, 2019
    Publication date: April 22, 2021
    Applicants: KYOTO UNIVERSITY, Astellas Pharma Inc.
    Inventors: Hideaki HARA, Shuh NARUMIYA, Tomohiro AOKI, Ichiro ARAMORI, Rie YAMAMOTO
  • Patent number: 10975091
    Abstract: The problem to be solved by the present invention is to provide a compound suitable for a pharmaceutical composition, specifically a pharmaceutically composition for treating nocturia. The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, would maintain and/or increase an endogenous AVP level to enhance the antidiuretic effect, which would contribute to a decreased number of nocturnal voids, and have extensively studied compounds which inhibit P-LAP. As a result, the inventors have found that (2R)-3-amino-2-{[4-(substituted pyridine)-2-yl]methyl}-2-hydroxy-propanoic acid derivatives have excellent P-LAP inhibitory activity. The inventors have evaluated antidiuretic effects in water-loaded rats and have found that the compounds increase endogenous AVP levels by inhibiting P-LAP and consequently reduce urine production.
    Type: Grant
    Filed: August 19, 2019
    Date of Patent: April 13, 2021
    Assignees: Astellas Pharma Inc., KOTOBUKI PHARMACEUTICAL CO., LTD.
    Inventors: Kenichi Kawaguchi, Akihiro Ishihata, Yusuke Inagaki, Kazuyuki Tsuchiya, Tadaatsu Hanadate, Akira Kanai, Hiroyuki Kaizawa, Junichi Kazami, Hiroshi Morikawa, Masashi Hiramoto, Kentaro Enjo, Hajime Takamatsu
  • Patent number: 10946069
    Abstract: The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as pancreatic cancer and metastases thereof.
    Type: Grant
    Filed: May 2, 2019
    Date of Patent: March 16, 2021
    Assignees: Astellas Pharma Inc., TRON-Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz
    Inventors: Ugur Sahin, Ozlem Tureci, Rita Mitnacht-Kraus, Stefan Woll, Stefan Jacobs, Cornelia Heinz